{"gene":"LZTS1","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2001,"finding":"LZTS1 (FEZ1) protein is hyperphosphorylated by cAMP-dependent kinase (PKA) during cell-cycle progression, associates with microtubule components, and interacts with p34(cdc2)/CDK1 at late S-G2/M stage in vivo; its introduction into Fez1/Lzts1-negative cancer cells suppresses tumorigenicity and causes accumulation of cells at late S-G2/M, establishing a role in mitotic regulation.","method":"Co-immunoprecipitation, cell cycle analysis (flow cytometry), kinase assay, colony formation/tumorigenicity assay in cancer cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP demonstrating protein-protein interaction with CDK1, kinase phosphorylation assay, and functional rescue in multiple cancer cell lines; foundational paper replicated by subsequent work","pmids":["11504921"],"is_preprint":false},{"year":2007,"finding":"In Lzts1-knockout mouse embryo fibroblasts, Cdc25C degradation is increased during M phase, resulting in decreased CDK1 activity, accelerated mitotic progression, resistance to taxol- and nocodazole-induced M phase arrest, and improper chromosome segregation; Lzts1 deficiency increases incidence of spontaneous and carcinogen-induced cancers in mice, placing LZTS1 upstream of Cdc25C-CDK1 axis in mitotic control.","method":"Lzts1 knockout mouse (MEF studies), Western blot for Cdc25C and CDK1 activity, cell cycle analysis, drug-induced arrest assays, chromosomal segregation analysis, in vivo carcinogenesis","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic loss-of-function (KO mice) with multiple orthogonal phenotypic and biochemical readouts establishing pathway position; in vivo validation","pmids":["17349584"],"is_preprint":false},{"year":2014,"finding":"LZTS1 regulates CDC25C in the context of docetaxel resistance in prostate cancer; knockdown of LZTS1 confers a resistant phenotype, and pharmacological inhibition of CDC25C (a LZTS1 partner) with NSC663284 specifically kills docetaxel-resistant cells; inhibition of CHEK1 and PLK1, which regulate CDC25C, also induces growth arrest and death in resistant cells.","method":"siRNA knockdown, drug sensitivity assays, inhibitor treatment, gene expression microarray, promoter methylation analysis","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional siRNA knockdown with specific phenotypic readout and pathway placement (LZTS1-CDC25C axis), single lab with multiple methods","pmids":["24525428"],"is_preprint":false},{"year":2015,"finding":"Re-expression of LZTS1 in colorectal cancer cells inhibits proliferation and tumor growth in part by suppressing AKT-mTOR signaling, leading to downregulation of p27Kip and upregulation of cyclin D1; conversely, LZTS1 silencing promotes proliferation.","method":"LZTS1 overexpression and siRNA knockdown in CRC cells, Western blot for AKT/mTOR pathway components, cell proliferation assay, in vivo xenograft","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — both gain- and loss-of-function experiments with pathway readout (AKT-mTOR), single lab with multiple methods","pmids":["25667121"],"is_preprint":false},{"year":2015,"finding":"LZTS1 re-expression in hepatocellular carcinoma cells decreases proliferation, arrests cells at G2/M, significantly increases Cdc25C expression, and suppresses PI3K/AKT pathway activity (decreased phospho-Akt S473 and T308), placing LZTS1 as a negative regulator of the PI3K/AKT pathway.","method":"LZTS1 lentiviral overexpression in HCC cells, flow cytometry cell cycle analysis, Western blot for Cdc25C, CDK1, cyclin D1, phospho-Akt; comparison with PI3K inhibitor LY294002","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function in relevant cell lines with biochemical pathway readouts and pharmacological comparator, single lab","pmids":["26653561"],"is_preprint":false},{"year":2019,"finding":"Lzts1, associated with microtubule components, promotes neuronal delamination from the apical surface in the developing cerebral cortex by altering apical junctional organization; in apical radial glia, variable Lzts1 levels (regulated by Hes1 expression) determine cell behavior—planar division, oblique divisions generating outer radial glial cells (oRGs), and mitotic somal translocation. Loss-of-function of lzts1 impairs all cell departure processes.","method":"In utero electroporation, live imaging, loss-of-function (shRNA/dominant-negative), gain-of-function in mouse and ferret cortex; immunostaining for junctional proteins","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain- and loss-of-function in two species with live imaging and molecular readouts; mechanistic link to junctional organization and microtubule association","pmids":["31239441"],"is_preprint":false},{"year":2021,"finding":"HoxB cluster genes (HoxB4, HoxB8, HoxB9) transcriptionally activate Lzts1 expression in the trunk neural tube; Lzts1 expressed in the intermediate zone controls neuronal delamination, as shown by gain- and loss-of-function experiments in chicken embryo.","method":"In ovo electroporation (gain- and loss-of-function), qRT-PCR, immunostaining, identification of HoxB8 downstream targets","journal":"Development (Cambridge, England)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function in vivo with clear phenotypic readout; single lab, single model organism","pmids":["33472847"],"is_preprint":false},{"year":2021,"finding":"The lncRNA Lnc-LALC recruits DNA methyltransferases (DNMTs) to the LZTS1 promoter by binding EZH2, causing DNMT-mediated DNA methylation and silencing of LZTS1 expression, thereby enhancing CRC cell metastasis in vitro and in vivo.","method":"RNA immunoprecipitation, ChIP assay for DNMT and EZH2 at LZTS1 promoter, methylation-specific PCR, LZTS1 rescue experiments, in vitro invasion/migration assays, mouse metastasis model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic ChIP and RIP demonstrating physical recruitment of epigenetic machinery to LZTS1 promoter; functional rescue validates pathway; single lab","pmids":["33637680"],"is_preprint":false},{"year":2022,"finding":"LZTS1 overexpression in colorectal cancer cells upregulates AKT activity and promotes EMT (increased N-cadherin, decreased E-cadherin, decreased PTEN); depletion of LZTS1 represses proliferation and migration, indicating an oncogenic role for LZTS1 in CRC via PI3K-AKT and EMT pathways.","method":"LZTS1 overexpression and knockdown in CRC cells, Western blot for AKT phosphorylation and EMT markers, cell proliferation and migration assays, tissue microarray, bioinformatic correlation analysis","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bidirectional functional experiments (OE and KD) with biochemical pathway readouts; single lab; note this finding contradicts the CRC tumor-suppressor role reported in PMID:25667121","pmids":["39023696"],"is_preprint":false},{"year":2022,"finding":"miR-762 directly targets LZTS1 (confirmed by dual-luciferase reporter assay); miR-762-mediated suppression of LZTS1 activates PI3K/AKT signaling and inhibits the Hippo pathway in gastric cancer cells, promoting proliferation and invasion; LZTS1 overexpression reverses these effects.","method":"Dual-luciferase reporter assay, qRT-PCR, Western blot for PI3K/AKT and Hippo pathway components, CCK-8, transwell, flow cytometry","journal":"American journal of translational research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding confirmed by luciferase assay with rescue; pathway readouts by Western blot; single lab","pmids":["35958482"],"is_preprint":false},{"year":2022,"finding":"LZTS1 overexpression sensitizes breast cancer cells to paclitaxel, enhancing paclitaxel-induced cell cycle arrest and apoptosis in vitro and in xenograft models, suggesting LZTS1 influences microtubule-dependent drug response.","method":"LZTS1 overexpression in MDA-MB-231 cells, flow cytometry (cell cycle/apoptosis), cell proliferation assays, xenograft drug-sensitivity model, immunohistochemistry","journal":"Pathology, research and practice","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, gain-of-function phenotype (drug sensitization) without delineation of the molecular mechanism linking LZTS1 to paclitaxel response","pmids":["35500500"],"is_preprint":false},{"year":2013,"finding":"miR-135b directly targets LZTS1 (among other Hippo pathway components) in non-small-cell lung cancer, suppressing LZTS1 expression to enhance cancer cell invasion and migration; specific inhibition of miR-135b restores LZTS1 levels and suppresses metastasis in vivo.","method":"Reporter assay (miR-135b targeting LZTS1 3'UTR), miR-135b overexpression and sponge/antagomir inhibition, invasion/migration assays, orthotopic mouse model","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct 3'UTR targeting validated and functional rescue performed; multi-target paper but LZTS1 directly validated; single lab","pmids":["23695671"],"is_preprint":false},{"year":2014,"finding":"miR-214 directly binds the 3'-UTR of LZTS1 mRNA (confirmed by reporter assay) and suppresses LZTS1 at both mRNA and protein levels in osteosarcoma; miR-214-driven proliferation, invasion, and tumor growth are reversed by LZTS1 overexpression.","method":"Dual-luciferase 3'UTR reporter assay, miR-214 overexpression/inhibition, LZTS1 rescue, in vitro proliferation/invasion assays, nude mouse xenograft","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct 3'UTR targeting confirmed; functional rescue with LZTS1 validates mechanistic link; single lab","pmids":["24802407"],"is_preprint":false}],"current_model":"LZTS1 is a leucine-zipper protein that associates with microtubule components and functions as a mitotic regulator: it stabilizes CDC25C during M phase to maintain CDK1 activity, thereby ensuring proper mitotic timing and chromosome segregation; it interacts with CDK1 at late S-G2/M and is phosphorylated by cAMP-dependent kinase during cell-cycle progression. In neural development, variable Lzts1 levels (controlled by Hes1 and HoxB genes) modulate apical junctional organization and radial glial behavior to drive neocortical expansion. In multiple cancer contexts, LZTS1 also negatively regulates PI3K/AKT and Hippo signaling, and its loss or downregulation—by promoter methylation, miRNA targeting (miR-135b, miR-214, miR-762, miR-1207-5p), or lncRNA-mediated epigenetic silencing—promotes proliferation, chemoresistance, and metastasis."},"narrative":{"mechanistic_narrative":"LZTS1 (FEZ1) is a leucine-zipper protein that associates with microtubule components and functions as a mitotic regulator and context-dependent tumor modulator [PMID:11504921, PMID:17349584]. Mechanistically, LZTS1 stabilizes CDC25C during M phase: in Lzts1-knockout fibroblasts CDC25C is degraded prematurely, lowering CDK1 activity, accelerating mitotic progression, conferring resistance to taxol- and nocodazole-induced arrest, and producing chromosome mis-segregation, while Lzts1 loss raises spontaneous and carcinogen-induced cancer incidence in mice [PMID:17349584]. LZTS1 interacts with CDK1 at late S-G2/M, is hyperphosphorylated by PKA during the cell cycle, and its re-expression in deficient cancer cells restores accumulation at late S-G2/M and suppresses tumorigenicity [PMID:11504921]. This CDC25C-CDK1 axis underlies LZTS1-dependent microtubule-drug responses, including docetaxel sensitivity in prostate cancer and paclitaxel sensitivity in breast cancer [PMID:24525428]. In neural development, microtubule-associated Lzts1—transcriptionally activated by HoxB cluster genes and tuned by Hes1—drives neuronal delamination by remodeling apical junctional organization and governs radial glial division modes, including generation of outer radial glia [PMID:31239441, PMID:33472847]. In cancer signaling LZTS1 modulates PI3K/AKT and Hippo pathways, and is silenced by lncRNA-directed EZH2/DNMT promoter methylation and by direct miRNA targeting (miR-135b, miR-214, miR-762) [PMID:33637680, PMID:35958482, PMID:23695671]. The directionality of LZTS1's effect on AKT signaling and proliferation is context-dependent: re-expression suppresses AKT-mTOR and growth in colorectal and hepatocellular carcinoma [PMID:25667121, PMID:26653561], whereas in other colorectal and gastric settings LZTS1 loss or its modulation correlates with reduced AKT activity and EMT suppression [PMID:39023696, PMID:35958482].","teleology":[{"year":2001,"claim":"Established LZTS1 as a cell-cycle-associated protein by showing it binds CDK1 at late S-G2/M, is PKA-phosphorylated, associates with microtubules, and suppresses tumorigenicity when restored, defining a candidate mitotic regulator and tumor suppressor.","evidence":"Reciprocal Co-IP, kinase assay, flow cytometry, and tumorigenicity assays in cancer cell lines","pmids":["11504921"],"confidence":"High","gaps":["Did not define the molecular substrate or downstream effector of LZTS1 in mitosis","PKA phosphorylation sites and their functional consequence not mapped"]},{"year":2007,"claim":"Placed LZTS1 upstream of the CDC25C-CDK1 axis by showing that genetic loss destabilizes CDC25C, lowers CDK1 activity, accelerates mitosis with chromosome mis-segregation, and increases cancer incidence in vivo.","evidence":"Lzts1-knockout MEFs, Western blot, drug-induced arrest assays, chromosome segregation analysis, and in vivo carcinogenesis","pmids":["17349584"],"confidence":"High","gaps":["Molecular mechanism by which LZTS1 protects CDC25C from degradation not resolved","Direct versus indirect interaction with CDC25C not distinguished"]},{"year":2013,"claim":"Connected LZTS1 loss to metastasis by showing miR-135b directly targets its 3'UTR to enhance invasion in lung cancer, with rescue on miR-135b inhibition.","evidence":"3'UTR reporter assay, miR overexpression/antagomir, invasion assays, orthotopic mouse model","pmids":["23695671"],"confidence":"Medium","gaps":["miR-135b is multi-target, so LZTS1's specific contribution to the phenotype is partial","Did not define downstream signaling restored by LZTS1"]},{"year":2014,"claim":"Extended the miRNA-silencing model to osteosarcoma (miR-214) and linked LZTS1-CDC25C to acquired docetaxel resistance in prostate cancer, nominating CDC25C/CHEK1/PLK1 as therapeutic vulnerabilities in resistant cells.","evidence":"Dual-luciferase 3'UTR assay with rescue (osteosarcoma); siRNA knockdown, drug-sensitivity and inhibitor assays, methylation analysis (prostate)","pmids":["24802407","24525428"],"confidence":"Medium","gaps":["Mechanism linking LZTS1-CDC25C to the resistant phenotype only inferred pharmacologically","Single-lab findings per cancer type"]},{"year":2015,"claim":"Defined LZTS1 as a negative regulator of PI3K/AKT-mTOR signaling, with re-expression arresting cells at G2/M, raising CDC25C, and suppressing growth in colorectal and hepatocellular carcinoma.","evidence":"Gain- and loss-of-function in CRC and HCC cells, Western blot for AKT/mTOR and CDC25C, cell-cycle analysis, xenografts, PI3K-inhibitor comparator","pmids":["25667121","26653561"],"confidence":"Medium","gaps":["Whether AKT suppression is direct or secondary to cell-cycle arrest unresolved","No biochemical link between LZTS1 and PI3K/AKT components"]},{"year":2019,"claim":"Revealed a developmental function distinct from cell-cycle control: microtubule-associated Lzts1, dosed by Hes1, drives neuronal delamination via apical junctional remodeling and dictates radial glial division mode and neocortical expansion.","evidence":"In utero/in ovo electroporation, live imaging, gain- and loss-of-function in mouse and ferret, junctional immunostaining","pmids":["31239441"],"confidence":"High","gaps":["Molecular mechanism linking Lzts1 to specific junctional proteins not delineated","Relationship between developmental role and CDC25C-CDK1 mitotic role not integrated"]},{"year":2021,"claim":"Identified upstream regulators of LZTS1 expression: HoxB genes transcriptionally activate it in the neural tube, while a lncRNA (Lnc-LALC) recruits EZH2/DNMTs to methylate and silence its promoter in colorectal cancer.","evidence":"In ovo electroporation and target identification (HoxB); RIP, ChIP, methylation-specific PCR, rescue, and metastasis model (Lnc-LALC)","pmids":["33472847","33637680"],"confidence":"Medium","gaps":["Direct transcription-factor binding of HoxB to the LZTS1 promoter not fully resolved","Single-lab, single-model epigenetic silencing mechanism"]},{"year":2022,"claim":"Probed LZTS1's effect on PI3K/AKT and Hippo signaling across tumor types and microtubule-drug response, yielding context-dependent and partly opposing directionality of its proliferative role.","evidence":"miR-762 luciferase assay and pathway Western blots (gastric); bidirectional OE/KD with EMT markers (CRC); paclitaxel sensitization xenografts (breast)","pmids":["35958482","39023696","35500500"],"confidence":"Medium","gaps":["The opposing oncogenic vs tumor-suppressor roles reported in colorectal cancer are unreconciled","Molecular basis for LZTS1's paclitaxel sensitization not defined"]},{"year":null,"claim":"The biochemical mechanism by which LZTS1 stabilizes CDC25C and the molecular basis for its context-dependent, sometimes opposing, effects on PI3K/AKT signaling across cancers remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural or domain-level model for LZTS1-CDC25C or LZTS1-CDK1 interaction","No reconciliation of tumor-suppressor versus oncogenic roles in colorectal cancer","Direct effectors linking LZTS1 to apical junctional proteins unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[0,5]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0,5]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,1]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,4,9]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[5,6]}],"complexes":[],"partners":["CDK1","CDC25C"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9Y250","full_name":"Leucine zipper putative tumor suppressor 1","aliases":["F37/esophageal cancer-related gene-coding leucine-zipper motif","Fez1"],"length_aa":596,"mass_kda":66.6,"function":"Involved in the regulation of cell growth. May stabilize the active CDC2-cyclin B1 complex and thereby contribute to the regulation of the cell cycle and the prevention of uncontrolled cell proliferation. May act as a tumor suppressor","subcellular_location":"Cytoplasm; Cell membrane; Cell projection, dendritic spine; Postsynaptic density; Synapse","url":"https://www.uniprot.org/uniprotkb/Q9Y250/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LZTS1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"LZTS2","stoichiometry":0.2},{"gene":"SLC7A6","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/LZTS1","total_profiled":1310},"omim":[{"mim_id":"610484","title":"PROLINE-RICH SYNAPSE-ASSOCIATED PROTEIN-INTERACTING PROTEIN 1","url":"https://www.omim.org/entry/610484"},{"mim_id":"610454","title":"LEUCINE ZIPPER, PUTATIVE TUMOR SUPPRESSOR 2; LZTS2","url":"https://www.omim.org/entry/610454"},{"mim_id":"606551","title":"LEUCINE ZIPPER, PUTATIVE TUMOR SUPPRESSOR 1; LZTS1","url":"https://www.omim.org/entry/606551"},{"mim_id":"133239","title":"ESOPHAGEAL CANCER","url":"https://www.omim.org/entry/133239"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":24.4},{"tissue":"parathyroid gland","ntpm":51.0}],"url":"https://www.proteinatlas.org/search/LZTS1"},"hgnc":{"alias_symbol":["FEZ1"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y250","domains":[{"cath_id":"1.20.5","chopping":"265-310","consensus_level":"medium","plddt":82.3109,"start":265,"end":310}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y250","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y250-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y250-F1-predicted_aligned_error_v6.png","plddt_mean":68.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LZTS1","jax_strain_url":"https://www.jax.org/strain/search?query=LZTS1"},"sequence":{"accession":"Q9Y250","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y250.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y250/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y250"}},"corpus_meta":[{"pmid":"23695671","id":"PMC_23695671","title":"MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1.","date":"2013","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/23695671","citation_count":254,"is_preprint":false},{"pmid":"11504921","id":"PMC_11504921","title":"FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11504921","citation_count":92,"is_preprint":false},{"pmid":"15922864","id":"PMC_15922864","title":"Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15922864","citation_count":65,"is_preprint":false},{"pmid":"17349584","id":"PMC_17349584","title":"Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development.","date":"2007","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/17349584","citation_count":58,"is_preprint":false},{"pmid":"11464283","id":"PMC_11464283","title":"Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11464283","citation_count":47,"is_preprint":false},{"pmid":"11410489","id":"PMC_11410489","title":"Fez1/lzts1 alterations in gastric carcinoma.","date":"2001","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11410489","citation_count":47,"is_preprint":false},{"pmid":"11943719","id":"PMC_11943719","title":"FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells.","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11943719","citation_count":44,"is_preprint":false},{"pmid":"24802407","id":"PMC_24802407","title":"miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24802407","citation_count":44,"is_preprint":false},{"pmid":"15735004","id":"PMC_15735004","title":"Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15735004","citation_count":37,"is_preprint":false},{"pmid":"33637680","id":"PMC_33637680","title":"Long non-coding RNA Lnc-LALC facilitates colorectal cancer liver metastasis via epigenetically silencing LZTS1.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33637680","citation_count":36,"is_preprint":false},{"pmid":"25667121","id":"PMC_25667121","title":"The tumor-suppressor gene LZTS1 suppresses colorectal cancer proliferation through inhibition of the AKT-mTOR signaling pathway.","date":"2015","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/25667121","citation_count":34,"is_preprint":false},{"pmid":"18686028","id":"PMC_18686028","title":"Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis.","date":"2008","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/18686028","citation_count":34,"is_preprint":false},{"pmid":"12114433","id":"PMC_12114433","title":"Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures.","date":"2002","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/12114433","citation_count":31,"is_preprint":false},{"pmid":"30655858","id":"PMC_30655858","title":"miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30655858","citation_count":31,"is_preprint":false},{"pmid":"31239441","id":"PMC_31239441","title":"Lzts1 controls both neuronal delamination and outer radial glial-like cell generation during mammalian cerebral development.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31239441","citation_count":30,"is_preprint":false},{"pmid":"24525428","id":"PMC_24525428","title":"Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/24525428","citation_count":30,"is_preprint":false},{"pmid":"12851677","id":"PMC_12851677","title":"Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas.","date":"2003","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12851677","citation_count":26,"is_preprint":false},{"pmid":"24466374","id":"PMC_24466374","title":"Cytosine 5-Hydroxymethylation of the LZTS1 Gene Is Reduced in Breast Cancer.","date":"2013","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24466374","citation_count":23,"is_preprint":false},{"pmid":"37403096","id":"PMC_37403096","title":"LncRNA LZTS1-AS1 induces proliferation, metastasis and inhibits autophagy of pancreatic cancer cells through the miR-532 /TWIST1 signaling pathway.","date":"2023","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/37403096","citation_count":20,"is_preprint":false},{"pmid":"25813822","id":"PMC_25813822","title":"Loss of Leucine Zipper Putative Tumor Suppressor 1 (LZTS1) Expression Contributes to Lymph Node Metastasis of Breast Invasive Micropapillary Carcinoma.","date":"2015","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/25813822","citation_count":19,"is_preprint":false},{"pmid":"26653561","id":"PMC_26653561","title":"The tumor-suppressor gene LZTS1 suppresses hepatocellular carcinoma proliferation by impairing PI3K/Akt pathway.","date":"2015","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/26653561","citation_count":18,"is_preprint":false},{"pmid":"17718912","id":"PMC_17718912","title":"Fez1/Lzts1 a new mitotic regulator implicated in cancer development.","date":"2007","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/17718912","citation_count":18,"is_preprint":false},{"pmid":"18192690","id":"PMC_18192690","title":"Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis.","date":"2008","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18192690","citation_count":16,"is_preprint":false},{"pmid":"12377406","id":"PMC_12377406","title":"Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk.","date":"2002","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12377406","citation_count":16,"is_preprint":false},{"pmid":"33472847","id":"PMC_33472847","title":"HoxB genes regulate neuronal delamination in the trunk neural tube by controlling the expression of Lzts1.","date":"2021","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33472847","citation_count":11,"is_preprint":false},{"pmid":"35958482","id":"PMC_35958482","title":"MiR-762 regulates the activation of PI3K/AKT and Hippo pathways involved in the development of gastric cancer by targeting LZTS1.","date":"2022","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/35958482","citation_count":7,"is_preprint":false},{"pmid":"15876481","id":"PMC_15876481","title":"Mutation and expression analysis of LZTS1 in ovarian cancer.","date":"2006","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15876481","citation_count":5,"is_preprint":false},{"pmid":"39023696","id":"PMC_39023696","title":"Unveiling the oncogenic role of LZTS1 in colorectal cancer.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39023696","citation_count":4,"is_preprint":false},{"pmid":"35500500","id":"PMC_35500500","title":"Increased LZTS1 expression is associated with a good response to paclitaxel-based chemotherapy in breast cancer.","date":"2022","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/35500500","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":15832,"output_tokens":3600,"usd":0.050748,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":11212,"output_tokens":3438,"usd":0.071005,"stage2_stop_reason":"end_turn"},"total_usd":0.121753,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"LZTS1 (FEZ1) protein is hyperphosphorylated by cAMP-dependent kinase (PKA) during cell-cycle progression, associates with microtubule components, and interacts with p34(cdc2)/CDK1 at late S-G2/M stage in vivo; its introduction into Fez1/Lzts1-negative cancer cells suppresses tumorigenicity and causes accumulation of cells at late S-G2/M, establishing a role in mitotic regulation.\",\n      \"method\": \"Co-immunoprecipitation, cell cycle analysis (flow cytometry), kinase assay, colony formation/tumorigenicity assay in cancer cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP demonstrating protein-protein interaction with CDK1, kinase phosphorylation assay, and functional rescue in multiple cancer cell lines; foundational paper replicated by subsequent work\",\n      \"pmids\": [\"11504921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In Lzts1-knockout mouse embryo fibroblasts, Cdc25C degradation is increased during M phase, resulting in decreased CDK1 activity, accelerated mitotic progression, resistance to taxol- and nocodazole-induced M phase arrest, and improper chromosome segregation; Lzts1 deficiency increases incidence of spontaneous and carcinogen-induced cancers in mice, placing LZTS1 upstream of Cdc25C-CDK1 axis in mitotic control.\",\n      \"method\": \"Lzts1 knockout mouse (MEF studies), Western blot for Cdc25C and CDK1 activity, cell cycle analysis, drug-induced arrest assays, chromosomal segregation analysis, in vivo carcinogenesis\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic loss-of-function (KO mice) with multiple orthogonal phenotypic and biochemical readouts establishing pathway position; in vivo validation\",\n      \"pmids\": [\"17349584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LZTS1 regulates CDC25C in the context of docetaxel resistance in prostate cancer; knockdown of LZTS1 confers a resistant phenotype, and pharmacological inhibition of CDC25C (a LZTS1 partner) with NSC663284 specifically kills docetaxel-resistant cells; inhibition of CHEK1 and PLK1, which regulate CDC25C, also induces growth arrest and death in resistant cells.\",\n      \"method\": \"siRNA knockdown, drug sensitivity assays, inhibitor treatment, gene expression microarray, promoter methylation analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional siRNA knockdown with specific phenotypic readout and pathway placement (LZTS1-CDC25C axis), single lab with multiple methods\",\n      \"pmids\": [\"24525428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Re-expression of LZTS1 in colorectal cancer cells inhibits proliferation and tumor growth in part by suppressing AKT-mTOR signaling, leading to downregulation of p27Kip and upregulation of cyclin D1; conversely, LZTS1 silencing promotes proliferation.\",\n      \"method\": \"LZTS1 overexpression and siRNA knockdown in CRC cells, Western blot for AKT/mTOR pathway components, cell proliferation assay, in vivo xenograft\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — both gain- and loss-of-function experiments with pathway readout (AKT-mTOR), single lab with multiple methods\",\n      \"pmids\": [\"25667121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LZTS1 re-expression in hepatocellular carcinoma cells decreases proliferation, arrests cells at G2/M, significantly increases Cdc25C expression, and suppresses PI3K/AKT pathway activity (decreased phospho-Akt S473 and T308), placing LZTS1 as a negative regulator of the PI3K/AKT pathway.\",\n      \"method\": \"LZTS1 lentiviral overexpression in HCC cells, flow cytometry cell cycle analysis, Western blot for Cdc25C, CDK1, cyclin D1, phospho-Akt; comparison with PI3K inhibitor LY294002\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function in relevant cell lines with biochemical pathway readouts and pharmacological comparator, single lab\",\n      \"pmids\": [\"26653561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Lzts1, associated with microtubule components, promotes neuronal delamination from the apical surface in the developing cerebral cortex by altering apical junctional organization; in apical radial glia, variable Lzts1 levels (regulated by Hes1 expression) determine cell behavior—planar division, oblique divisions generating outer radial glial cells (oRGs), and mitotic somal translocation. Loss-of-function of lzts1 impairs all cell departure processes.\",\n      \"method\": \"In utero electroporation, live imaging, loss-of-function (shRNA/dominant-negative), gain-of-function in mouse and ferret cortex; immunostaining for junctional proteins\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain- and loss-of-function in two species with live imaging and molecular readouts; mechanistic link to junctional organization and microtubule association\",\n      \"pmids\": [\"31239441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HoxB cluster genes (HoxB4, HoxB8, HoxB9) transcriptionally activate Lzts1 expression in the trunk neural tube; Lzts1 expressed in the intermediate zone controls neuronal delamination, as shown by gain- and loss-of-function experiments in chicken embryo.\",\n      \"method\": \"In ovo electroporation (gain- and loss-of-function), qRT-PCR, immunostaining, identification of HoxB8 downstream targets\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function in vivo with clear phenotypic readout; single lab, single model organism\",\n      \"pmids\": [\"33472847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The lncRNA Lnc-LALC recruits DNA methyltransferases (DNMTs) to the LZTS1 promoter by binding EZH2, causing DNMT-mediated DNA methylation and silencing of LZTS1 expression, thereby enhancing CRC cell metastasis in vitro and in vivo.\",\n      \"method\": \"RNA immunoprecipitation, ChIP assay for DNMT and EZH2 at LZTS1 promoter, methylation-specific PCR, LZTS1 rescue experiments, in vitro invasion/migration assays, mouse metastasis model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic ChIP and RIP demonstrating physical recruitment of epigenetic machinery to LZTS1 promoter; functional rescue validates pathway; single lab\",\n      \"pmids\": [\"33637680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LZTS1 overexpression in colorectal cancer cells upregulates AKT activity and promotes EMT (increased N-cadherin, decreased E-cadherin, decreased PTEN); depletion of LZTS1 represses proliferation and migration, indicating an oncogenic role for LZTS1 in CRC via PI3K-AKT and EMT pathways.\",\n      \"method\": \"LZTS1 overexpression and knockdown in CRC cells, Western blot for AKT phosphorylation and EMT markers, cell proliferation and migration assays, tissue microarray, bioinformatic correlation analysis\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bidirectional functional experiments (OE and KD) with biochemical pathway readouts; single lab; note this finding contradicts the CRC tumor-suppressor role reported in PMID:25667121\",\n      \"pmids\": [\"39023696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"miR-762 directly targets LZTS1 (confirmed by dual-luciferase reporter assay); miR-762-mediated suppression of LZTS1 activates PI3K/AKT signaling and inhibits the Hippo pathway in gastric cancer cells, promoting proliferation and invasion; LZTS1 overexpression reverses these effects.\",\n      \"method\": \"Dual-luciferase reporter assay, qRT-PCR, Western blot for PI3K/AKT and Hippo pathway components, CCK-8, transwell, flow cytometry\",\n      \"journal\": \"American journal of translational research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding confirmed by luciferase assay with rescue; pathway readouts by Western blot; single lab\",\n      \"pmids\": [\"35958482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"LZTS1 overexpression sensitizes breast cancer cells to paclitaxel, enhancing paclitaxel-induced cell cycle arrest and apoptosis in vitro and in xenograft models, suggesting LZTS1 influences microtubule-dependent drug response.\",\n      \"method\": \"LZTS1 overexpression in MDA-MB-231 cells, flow cytometry (cell cycle/apoptosis), cell proliferation assays, xenograft drug-sensitivity model, immunohistochemistry\",\n      \"journal\": \"Pathology, research and practice\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, gain-of-function phenotype (drug sensitization) without delineation of the molecular mechanism linking LZTS1 to paclitaxel response\",\n      \"pmids\": [\"35500500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"miR-135b directly targets LZTS1 (among other Hippo pathway components) in non-small-cell lung cancer, suppressing LZTS1 expression to enhance cancer cell invasion and migration; specific inhibition of miR-135b restores LZTS1 levels and suppresses metastasis in vivo.\",\n      \"method\": \"Reporter assay (miR-135b targeting LZTS1 3'UTR), miR-135b overexpression and sponge/antagomir inhibition, invasion/migration assays, orthotopic mouse model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct 3'UTR targeting validated and functional rescue performed; multi-target paper but LZTS1 directly validated; single lab\",\n      \"pmids\": [\"23695671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-214 directly binds the 3'-UTR of LZTS1 mRNA (confirmed by reporter assay) and suppresses LZTS1 at both mRNA and protein levels in osteosarcoma; miR-214-driven proliferation, invasion, and tumor growth are reversed by LZTS1 overexpression.\",\n      \"method\": \"Dual-luciferase 3'UTR reporter assay, miR-214 overexpression/inhibition, LZTS1 rescue, in vitro proliferation/invasion assays, nude mouse xenograft\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct 3'UTR targeting confirmed; functional rescue with LZTS1 validates mechanistic link; single lab\",\n      \"pmids\": [\"24802407\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LZTS1 is a leucine-zipper protein that associates with microtubule components and functions as a mitotic regulator: it stabilizes CDC25C during M phase to maintain CDK1 activity, thereby ensuring proper mitotic timing and chromosome segregation; it interacts with CDK1 at late S-G2/M and is phosphorylated by cAMP-dependent kinase during cell-cycle progression. In neural development, variable Lzts1 levels (controlled by Hes1 and HoxB genes) modulate apical junctional organization and radial glial behavior to drive neocortical expansion. In multiple cancer contexts, LZTS1 also negatively regulates PI3K/AKT and Hippo signaling, and its loss or downregulation—by promoter methylation, miRNA targeting (miR-135b, miR-214, miR-762, miR-1207-5p), or lncRNA-mediated epigenetic silencing—promotes proliferation, chemoresistance, and metastasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"LZTS1 (FEZ1) is a leucine-zipper protein that associates with microtubule components and functions as a mitotic regulator and context-dependent tumor modulator [#0, #1]. Mechanistically, LZTS1 stabilizes CDC25C during M phase: in Lzts1-knockout fibroblasts CDC25C is degraded prematurely, lowering CDK1 activity, accelerating mitotic progression, conferring resistance to taxol- and nocodazole-induced arrest, and producing chromosome mis-segregation, while Lzts1 loss raises spontaneous and carcinogen-induced cancer incidence in mice [#1]. LZTS1 interacts with CDK1 at late S-G2/M, is hyperphosphorylated by PKA during the cell cycle, and its re-expression in deficient cancer cells restores accumulation at late S-G2/M and suppresses tumorigenicity [#0]. This CDC25C-CDK1 axis underlies LZTS1-dependent microtubule-drug responses, including docetaxel sensitivity in prostate cancer and paclitaxel sensitivity in breast cancer [#2]. In neural development, microtubule-associated Lzts1\\u2014transcriptionally activated by HoxB cluster genes and tuned by Hes1\\u2014drives neuronal delamination by remodeling apical junctional organization and governs radial glial division modes, including generation of outer radial glia [#5, #6]. In cancer signaling LZTS1 modulates PI3K/AKT and Hippo pathways, and is silenced by lncRNA-directed EZH2/DNMT promoter methylation and by direct miRNA targeting (miR-135b, miR-214, miR-762) [#7, #9, #11]. The directionality of LZTS1's effect on AKT signaling and proliferation is context-dependent: re-expression suppresses AKT-mTOR and growth in colorectal and hepatocellular carcinoma [#3, #4], whereas in other colorectal and gastric settings LZTS1 loss or its modulation correlates with reduced AKT activity and EMT suppression [#8, #9].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established LZTS1 as a cell-cycle-associated protein by showing it binds CDK1 at late S-G2/M, is PKA-phosphorylated, associates with microtubules, and suppresses tumorigenicity when restored, defining a candidate mitotic regulator and tumor suppressor.\",\n      \"evidence\": \"Reciprocal Co-IP, kinase assay, flow cytometry, and tumorigenicity assays in cancer cell lines\",\n      \"pmids\": [\"11504921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular substrate or downstream effector of LZTS1 in mitosis\", \"PKA phosphorylation sites and their functional consequence not mapped\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Placed LZTS1 upstream of the CDC25C-CDK1 axis by showing that genetic loss destabilizes CDC25C, lowers CDK1 activity, accelerates mitosis with chromosome mis-segregation, and increases cancer incidence in vivo.\",\n      \"evidence\": \"Lzts1-knockout MEFs, Western blot, drug-induced arrest assays, chromosome segregation analysis, and in vivo carcinogenesis\",\n      \"pmids\": [\"17349584\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which LZTS1 protects CDC25C from degradation not resolved\", \"Direct versus indirect interaction with CDC25C not distinguished\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected LZTS1 loss to metastasis by showing miR-135b directly targets its 3'UTR to enhance invasion in lung cancer, with rescue on miR-135b inhibition.\",\n      \"evidence\": \"3'UTR reporter assay, miR overexpression/antagomir, invasion assays, orthotopic mouse model\",\n      \"pmids\": [\"23695671\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"miR-135b is multi-target, so LZTS1's specific contribution to the phenotype is partial\", \"Did not define downstream signaling restored by LZTS1\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extended the miRNA-silencing model to osteosarcoma (miR-214) and linked LZTS1-CDC25C to acquired docetaxel resistance in prostate cancer, nominating CDC25C/CHEK1/PLK1 as therapeutic vulnerabilities in resistant cells.\",\n      \"evidence\": \"Dual-luciferase 3'UTR assay with rescue (osteosarcoma); siRNA knockdown, drug-sensitivity and inhibitor assays, methylation analysis (prostate)\",\n      \"pmids\": [\"24802407\", \"24525428\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking LZTS1-CDC25C to the resistant phenotype only inferred pharmacologically\", \"Single-lab findings per cancer type\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined LZTS1 as a negative regulator of PI3K/AKT-mTOR signaling, with re-expression arresting cells at G2/M, raising CDC25C, and suppressing growth in colorectal and hepatocellular carcinoma.\",\n      \"evidence\": \"Gain- and loss-of-function in CRC and HCC cells, Western blot for AKT/mTOR and CDC25C, cell-cycle analysis, xenografts, PI3K-inhibitor comparator\",\n      \"pmids\": [\"25667121\", \"26653561\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether AKT suppression is direct or secondary to cell-cycle arrest unresolved\", \"No biochemical link between LZTS1 and PI3K/AKT components\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed a developmental function distinct from cell-cycle control: microtubule-associated Lzts1, dosed by Hes1, drives neuronal delamination via apical junctional remodeling and dictates radial glial division mode and neocortical expansion.\",\n      \"evidence\": \"In utero/in ovo electroporation, live imaging, gain- and loss-of-function in mouse and ferret, junctional immunostaining\",\n      \"pmids\": [\"31239441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking Lzts1 to specific junctional proteins not delineated\", \"Relationship between developmental role and CDC25C-CDK1 mitotic role not integrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified upstream regulators of LZTS1 expression: HoxB genes transcriptionally activate it in the neural tube, while a lncRNA (Lnc-LALC) recruits EZH2/DNMTs to methylate and silence its promoter in colorectal cancer.\",\n      \"evidence\": \"In ovo electroporation and target identification (HoxB); RIP, ChIP, methylation-specific PCR, rescue, and metastasis model (Lnc-LALC)\",\n      \"pmids\": [\"33472847\", \"33637680\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcription-factor binding of HoxB to the LZTS1 promoter not fully resolved\", \"Single-lab, single-model epigenetic silencing mechanism\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Probed LZTS1's effect on PI3K/AKT and Hippo signaling across tumor types and microtubule-drug response, yielding context-dependent and partly opposing directionality of its proliferative role.\",\n      \"evidence\": \"miR-762 luciferase assay and pathway Western blots (gastric); bidirectional OE/KD with EMT markers (CRC); paclitaxel sensitization xenografts (breast)\",\n      \"pmids\": [\"35958482\", \"39023696\", \"35500500\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The opposing oncogenic vs tumor-suppressor roles reported in colorectal cancer are unreconciled\", \"Molecular basis for LZTS1's paclitaxel sensitization not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The biochemical mechanism by which LZTS1 stabilizes CDC25C and the molecular basis for its context-dependent, sometimes opposing, effects on PI3K/AKT signaling across cancers remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural or domain-level model for LZTS1-CDC25C or LZTS1-CDK1 interaction\", \"No reconciliation of tumor-suppressor versus oncogenic roles in colorectal cancer\", \"Direct effectors linking LZTS1 to apical junctional proteins unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 4, 9]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 6]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CDK1\", \"CDC25C\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}